{"id":"placebo-to-telcagepant-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Liver enzyme elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Telcagepant works by antagonizing the calcitonin gene-related peptide receptor, a key mediator in migraine pathophysiology. By blocking CGRP receptor signaling in the trigeminal system and central nervous system, it reduces the neuroinflammatory cascade that leads to migraine headaches. This mechanism addresses the underlying biology of migraine rather than just treating acute symptoms.","oneSentence":"Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine attacks.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:58.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention"}]},"trialDetails":[{"nctId":"NCT00758836","phase":"PHASE2","title":"A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-03","conditions":"Migraine","enrollment":683},{"nctId":"NCT00662818","phase":"PHASE3","title":"Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-17","conditions":"Migraine Disorders, Heart Disease, Cerebrovascular Accident","enrollment":165},{"nctId":"NCT01294709","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-12","conditions":"Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor","enrollment":64},{"nctId":"NCT00442936","phase":"PHASE3","title":"Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-15","conditions":"Migraine","enrollment":1380},{"nctId":"NCT00443209","phase":"PHASE3","title":"Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-21","conditions":"Migraine","enrollment":1068},{"nctId":"NCT00701389","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-20","conditions":"Migraine Disorders","enrollment":24},{"nctId":"NCT00432237","phase":"PHASE3","title":"Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03","conditions":"Migraine","enrollment":1703}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to telcagepant capsules","genericName":"Placebo to telcagepant capsules","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine attacks. Used for Migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}